toxylact: a03ab06 otilonium bromide

The first professional lActological database in the word

Otilonium bromide (ATC A03AB06) appears compatible with breastfeeding, given its minimal systemic absorption and very low likelihood of clinically relevant transfer into breast milk, though formal milk-level data are lacking and routine clinical monitoring of the infant remains advisable.medpedia.framar+3

Pharmacological profile

Otilonium bromide is a synthetic quaternary ammonium anticholinergic agent with a potent spasmolytic effect on gastrointestinal smooth muscle, used mainly for functional bowel disorders such as irritable bowel syndrome and other motility‐related abdominal pain syndromes. It acts predominantly at the level of the intestinal wall, reducing smooth muscle contractility and visceral hypersensitivity, with negligible systemic absorption after oral administration.e-lactation+4

Systemic exposure and disposition

After oral dosing, absorption of otilonium bromide from the gastrointestinal tract is described as practically absent, with almost all of the administered dose excreted unchanged in the feces. Reported plasma levels are extremely low (below 0.02 mg/L in available pharmacokinetic data), consistent with a largely local action in the intestinal lumen and wall. This combination of minimal bioavailability and high fecal excretion implies a very limited systemic exposure in the mother, which is a key determinant of the low expected exposure in breastfed infants.medsafe+1

Transfer into breast milk

No direct measurements of otilonium bromide concentrations in human milk have been published to date. However, the pharmacokinetic characteristics—poor oral absorption, extremely low plasma levels, and quaternary ammonium structure—suggest that clinically significant passage into breast milk is very unlikely. Expert lactation references therefore consider otilonium bromide compatible with breastfeeding (low risk), while recommending routine clinical follow‑up of the infant due to the absence of direct milk data.synapse.patsnap+5

Expected effects in breastfed infants

Given the negligible maternal plasma concentrations and the poor oral bioavailability of otilonium bromide, any drug that might reach breast milk would likely lead to sub‑therapeutic, clinically irrelevant doses in the breastfed infant. Consequently, anticholinergic adverse effects such as constipation, dry mouth, urinary retention, or tachycardia in the infant are not expected, though prudent monitoring for unusual gastrointestinal symptoms, altered feeding, or irritability remains good clinical practice.pmc.ncbi.nlm.nih+2

Impact on lactation physiology

Antimuscarinic agents can theoretically reduce milk production by inhibiting cholinergic stimulation of prolactin secretion and affecting let‑down, which has led to caution with some systemic anticholinergics. In the specific case of otilonium bromide, its minimal systemic absorption makes a clinically meaningful effect on prolactin levels or milk ejection highly improbable, and current expert opinion does not report cases of lactation suppression attributable to this drug.sps+3

Clinical use in lactating patients

Otilonium bromide is prescribed for irritable bowel syndrome and related functional gastrointestinal disorders characterized by abdominal pain, spasm, and motility disturbances, typically as oral tablets taken two to three times daily. In lactating women with IBS or functional bowel symptoms, otilonium bromide can be considered when first‑line options (such as peppermint oil, mebeverine, or hyoscine butylbromide) are unsuitable, ineffective, or poorly tolerated, taking into account the overall risk–benefit balance for mother and infant.apollopharmacy+6

Safety classification in lactation

Specialized lactation resources classify otilonium bromide as a low‑risk medication during breastfeeding, describing it as compatible and not risky for the breastfed infant under usual clinical conditions. This classification reflects both its pharmacokinetic profile and the absence of reported adverse outcomes in breastfed infants, while acknowledging the lack of direct milk pharmacokinetic studies.apilam+3

Duration–risk considerations

For short‑term or intermittent use in breastfeeding women, the combination of very low maternal systemic exposure and low oral bioavailability in the infant indicates a very low risk of cumulative toxicity. In longer‑term, chronic use for functional gastrointestinal disorders, continued breastfeeding is generally acceptable with periodic reassessment of maternal benefit, infant growth, feeding patterns, and gastrointestinal function, adjusting therapy if any unexpected symptoms arise in the child.e-lactation+3

Comparative context within gastrointestinal antispasmodics

Within the broader class of gastrointestinal antispasmodics used during breastfeeding, agents such as peppermint oil, mebeverine, hyoscine butylbromide, and propantheline are often cited as preferred options due to established experience and data. Otilonium bromide occupies a niche as a locally acting anticholinergic spasmolytic with favorable theoretical safety in lactation but relatively limited clinical lactation‑specific evidence compared with some older agents, which may influence local guideline preferences.breastfeedingnetwork+3

Practical recommendations for healthcare professionals

When prescribing otilonium bromide to a breastfeeding woman, clinicians should confirm the indication (typically IBS or functional bowel spasm), use the lowest effective dose, and regularly review symptom control and ongoing need for therapy. Breastfeeding can usually be continued without interruption, provided the infant is monitored for changes in feeding, weight gain, stool pattern, and behavior, with consideration of alternative antispasmodics if any concerning signs develop.pmc.ncbi.nlm.nih+4

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.